Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab Plus Tazemetostat for Relapsed/Refractory Follicular Lymphoma
NCT06575686Phase 2Suspended
- Sponsor
- City of Hope
- Start
- Mar 2025
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab, tazemetostat in follicular lymphoma (FL), sponsored by City of Hope. Started Mar 2025; status: suspended.
02
Drugs
epcoritamabtazemetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06575686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575686.